Fagron NV
XBRU:FAGR
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
16.56
19.68
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one FAGR stock under the Base Case scenario is 25.57 EUR. Compared to the current market price of 18.74 EUR, Fagron NV is Undervalued by 27%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Fagron NV
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for FAGR cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Fagron NV
Balance Sheet Decomposition
Fagron NV
Current Assets | 348.2m |
Cash & Short-Term Investments | 98.3m |
Receivables | 117.5m |
Other Current Assets | 132.4m |
Non-Current Assets | 696.8m |
Long-Term Investments | 5.8m |
PP&E | 164.8m |
Intangibles | 496.8m |
Other Non-Current Assets | 29.5m |
Current Liabilities | 200.5m |
Accounts Payable | 117.1m |
Accrued Liabilities | 37.5m |
Other Current Liabilities | 45.9m |
Non-Current Liabilities | 371.5m |
Long-Term Debt | 361.3m |
Other Non-Current Liabilities | 10.2m |
Earnings Waterfall
Fagron NV
Revenue
|
820.8m
EUR
|
Cost of Revenue
|
-458.2m
EUR
|
Gross Profit
|
362.5m
EUR
|
Operating Expenses
|
-243m
EUR
|
Operating Income
|
119.6m
EUR
|
Other Expenses
|
-41.6m
EUR
|
Net Income
|
77.9m
EUR
|
Free Cash Flow Analysis
Fagron NV
EUR | |
Free Cash Flow | EUR |
Fagron achieved 12.8% organic growth, pushing revenues to EUR 429 million in H1 2024. EBITDA margin rose to 19.7%. Full-year revenue guidance was upgraded to EUR 850-870 million with improved profitability expected. Regional performances were highlighted, with North America leading with 26.2% growth, driven by compounding services' 36% increase. EMEA faced Poland reimbursement challenges but grew 3.3%. LATAM grew 5.7%, focusing on innovation. The company announced EUR 50 million and $39 million investments in their Netherlands and Wichita facilities, respectively, to expand capacity and product offerings.
What is Earnings Call?
FAGR Profitability Score
Profitability Due Diligence
Fagron NV's profitability score is 60/100. The higher the profitability score, the more profitable the company is.
Score
Fagron NV's profitability score is 60/100. The higher the profitability score, the more profitable the company is.
FAGR Solvency Score
Solvency Due Diligence
Fagron NV's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Score
Fagron NV's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
FAGR Price Targets Summary
Fagron NV
According to Wall Street analysts, the average 1-year price target for FAGR is 22.1 EUR with a low forecast of 19.7 EUR and a high forecast of 25.2 EUR.
Dividends
Current shareholder yield for FAGR is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Fagron NV engages in the development, marketing, and distribution of healthcare products and services. The company is headquartered in Nazareth, Oost-Vlaanderen and currently employs 3,061 full-time employees. The company went IPO on 2007-10-05. The company operates as a research and development (R&D) scientific pharmaceutical compounding supplier and operates through four segments: The Fagron Specialty Pharma Services segment comprises personalized medication that is produced in the Company's compounding facilities; the Fagron Trademarks segment encompasses concepts and formulations developed by the Company's research and development (R&D) team; Fagron Essentials comprises pharmaceutical raw materials, equipment and supplies for pharmacies, and the HL Technology segment includes the development and production of precision components and orthopedic tools for dental and medical professionals.
Contact
IPO
Employees
Officers
The intrinsic value of one FAGR stock under the Base Case scenario is 25.57 EUR.
Compared to the current market price of 18.74 EUR, Fagron NV is Undervalued by 27%.